GB201118656D0 - New compounds - Google Patents

New compounds

Info

Publication number
GB201118656D0
GB201118656D0 GBGB1118656.6A GB201118656A GB201118656D0 GB 201118656 D0 GB201118656 D0 GB 201118656D0 GB 201118656 A GB201118656 A GB 201118656A GB 201118656 D0 GB201118656 D0 GB 201118656D0
Authority
GB
United Kingdom
Prior art keywords
compounds
new compounds
cancer
diseases
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1118656.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Priority to GBGB1118656.6A priority Critical patent/GB201118656D0/en
Publication of GB201118656D0 publication Critical patent/GB201118656D0/en
Priority to JOP/2012/0308A priority patent/JO3419B1/ar
Priority to TW101139220A priority patent/TWI602814B/zh
Priority to ARP120104039A priority patent/AR088567A1/es
Priority to NZ622702A priority patent/NZ622702B2/en
Priority to AP2014007540A priority patent/AP4060A/en
Priority to BR112014010206A priority patent/BR112014010206B8/pt
Priority to AU2012328170A priority patent/AU2012328170B2/en
Priority to US14/354,832 priority patent/US9309242B2/en
Priority to CN201280065190.4A priority patent/CN104011051B/zh
Priority to EA201490891A priority patent/EA027563B1/ru
Priority to DK12794745.5T priority patent/DK2776435T3/en
Priority to PH1/2014/500867A priority patent/PH12014500867A1/en
Priority to MYPI2014001207A priority patent/MY185666A/en
Priority to IN948MUN2014 priority patent/IN2014MN00948A/en
Priority to PCT/GB2012/052672 priority patent/WO2013061080A1/en
Priority to CA2853390A priority patent/CA2853390C/en
Priority to MX2014004855A priority patent/MX353654B/es
Priority to ES12794745.5T priority patent/ES2688868T3/es
Priority to UAA201405742A priority patent/UA111386C2/uk
Priority to SG11201401055XA priority patent/SG11201401055XA/en
Priority to SI201231385T priority patent/SI2776435T1/sl
Priority to EP12794745.5A priority patent/EP2776435B1/en
Priority to KR1020147010849A priority patent/KR102066496B1/ko
Priority to JP2014537730A priority patent/JP6169583B2/ja
Priority to HRP20181533TT priority patent/HRP20181533T1/hr
Priority to LTEP12794745.5T priority patent/LT2776435T/lt
Priority to UY0001034418A priority patent/UY34418A/es
Priority to IL232083A priority patent/IL232083B/en
Priority to CO14086785A priority patent/CO6940422A2/es
Priority to CR20140190A priority patent/CR20140190A/es
Priority to NI201400032A priority patent/NI201400032A/es
Priority to CL2014001065A priority patent/CL2014001065A1/es
Priority to ECSP14013325 priority patent/ECSP14013325A/es
Priority to US15/019,563 priority patent/US10045982B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB1118656.6A 2011-10-28 2011-10-28 New compounds Ceased GB201118656D0 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
GBGB1118656.6A GB201118656D0 (en) 2011-10-28 2011-10-28 New compounds
JOP/2012/0308A JO3419B1 (ar) 2011-10-28 2012-10-15 مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
TW101139220A TWI602814B (zh) 2011-10-28 2012-10-24 透過抑制fgfr激酶之具有抗癌性的吡啶並吡嗪衍生物化合物
UY0001034418A UY34418A (es) 2011-10-28 2012-10-26 Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia
CA2853390A CA2853390C (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of fgfr kinases
SG11201401055XA SG11201401055XA (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of fgfr kinases
AP2014007540A AP4060A (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of fgfr kinases
BR112014010206A BR112014010206B8 (pt) 2011-10-28 2012-10-26 composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
AU2012328170A AU2012328170B2 (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of FGFR kinases
US14/354,832 US9309242B2 (en) 2011-10-28 2012-10-26 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
CN201280065190.4A CN104011051B (zh) 2011-10-28 2012-10-26 通过fgfr激酶抑制抗癌的吡啶并吡嗪
EA201490891A EA027563B1 (ru) 2011-10-28 2012-10-26 Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
DK12794745.5T DK2776435T3 (en) 2011-10-28 2012-10-26 ANTICANCER PYRIDOPYRAZINES BY INHIBITION OF FGFR KINASES
PH1/2014/500867A PH12014500867A1 (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of fgfr kinases
MYPI2014001207A MY185666A (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of fgfr kinases
IN948MUN2014 IN2014MN00948A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-10-28 2012-10-26
PCT/GB2012/052672 WO2013061080A1 (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of fgfr kinases
ARP120104039A AR088567A1 (es) 2011-10-28 2012-10-26 Derivados de piridopiridazina
MX2014004855A MX353654B (es) 2011-10-28 2012-10-26 Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
ES12794745.5T ES2688868T3 (es) 2011-10-28 2012-10-26 Piridopirazinas anticáncer a través de la inhibición de FGFR quinasas
UAA201405742A UA111386C2 (uk) 2011-10-28 2012-10-26 Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
NZ622702A NZ622702B2 (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of fgfr kinases
SI201231385T SI2776435T1 (sl) 2011-10-28 2012-10-26 Antikancerogeni piridopirazini preko inhibicije FGFR kinaz
EP12794745.5A EP2776435B1 (en) 2011-10-28 2012-10-26 Anticancer pyridopyrazines via the inhibition of fgfr kinases
KR1020147010849A KR102066496B1 (ko) 2011-10-28 2012-10-26 Fgfr 키나제의 억제를 통한 항암 피리도피라진
JP2014537730A JP6169583B2 (ja) 2011-10-28 2012-10-26 Ｆｇｆｒキナーゼの阻害を介した抗癌ピリドピラジン
HRP20181533TT HRP20181533T1 (hr) 2011-10-28 2012-10-26 Antikancerogeni piridopirazini putem inhibitora fgfr kinaze
LTEP12794745.5T LT2776435T (lt) 2011-10-28 2012-10-26 Piridopirazinų priešvėžinis poveikis per fgfr kinazių slopinimą
IL232083A IL232083B (en) 2011-10-28 2014-04-10 Anticancer pyridopyrazines by inhibiting fgfr kinases
CO14086785A CO6940422A2 (es) 2011-10-28 2014-04-23 Piridopirazinas anticancerigenas via la inhibición de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
CR20140190A CR20140190A (es) 2011-10-28 2014-04-25 Piridopirazinas anticancerigenas via la inhibición de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
NI201400032A NI201400032A (es) 2011-10-28 2014-04-25 Piridopirazinas anticancerígenas via la
CL2014001065A CL2014001065A1 (es) 2011-10-28 2014-04-25 Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
ECSP14013325 ECSP14013325A (es) 2011-10-28 2014-04-28 Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
US15/019,563 US10045982B2 (en) 2011-10-28 2016-02-09 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1118656.6A GB201118656D0 (en) 2011-10-28 2011-10-28 New compounds

Publications (1)

Publication Number Publication Date
GB201118656D0 true GB201118656D0 (en) 2011-12-07

Family

ID=45373584

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1118656.6A Ceased GB201118656D0 (en) 2011-10-28 2011-10-28 New compounds

Country Status (33)

Country Link
US (2) US9309242B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2776435B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6169583B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102066496B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104011051B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP4060A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR088567A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012328170B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014010206B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2853390C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014001065A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO6940422A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20140190A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2776435T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA027563B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP14013325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2688868T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB201118656D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20181533T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL232083B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014MN00948A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO3419B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2776435T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX353654B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY185666A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NI (1) NI201400032A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014500867A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201401055XA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2776435T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI602814B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA111386C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY34418A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013061080A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
PT3060563T (pt) * 2013-10-25 2018-07-26 Novartis Ag Derivados piridilo biciclicos com anéis fundidos como inibidores do fgfr4
AR098145A1 (es) * 2013-10-25 2016-05-04 Novartis Ag Compuestos derivados de piridilo bicíclicos fusionados como inhibidores de fgfr4
WO2015144804A1 (en) * 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022062B1 (pt) * 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
PL3200786T3 (pl) * 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
BR112018005625B1 (pt) 2015-09-23 2023-11-14 Janssen Pharmaceutica N.V Compostos derivados de quinolina, piridopirazina, naftiridina e quinazolinona, composições farmacêuticas que os compreende e uso dos mesmos
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
CA3002560A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
WO2017164705A1 (ko) * 2016-03-24 2017-09-28 재단법인 대구경북첨단의료산업진흥재단 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물
EP3498707A4 (en) * 2016-08-12 2020-04-08 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. FGFR4 INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF
CN108101857B (zh) * 2016-11-24 2021-09-03 韶远科技（上海)有限公司 制取2-氨基-3-溴-6-氯吡嗪的可放大工艺
CN108264510A (zh) * 2017-01-02 2018-07-10 上海喆邺生物科技有限公司 一种选择性抑制激酶化合物及其用途
KR20200135945A (ko) 2018-03-28 2020-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종 치료제
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
WO2021146163A1 (en) * 2020-01-17 2021-07-22 Beta Pharma, Inc. Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors
KR20230152654A (ko) 2020-12-30 2023-11-03 타이라 바이오사이언시스, 인크. 키나아제 억제제로서의 인다졸 화합물
EP4297873A1 (en) 2021-02-26 2024-01-03 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
JP2025525434A (ja) 2022-06-29 2025-08-05 タイラ・バイオサイエンシーズ・インコーポレイテッド 多形化合物及びその使用
AU2023300362A1 (en) 2022-06-29 2025-01-09 Tyra Biosciences, Inc. Indazole compounds
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
WO2025129014A1 (en) 2023-12-15 2025-06-19 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
EP0763537A3 (en) 1993-05-14 1997-10-22 Genentech Inc Non-peptides farnesyl transfer inhibitors
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
DE69842151D1 (de) 1997-05-28 2011-04-14 Aventis Pharma Inc CHINOLIN UND CHINOXALINVERBINDUNGEN DIE DEN VON BLUTPLÄTTCHEN ABSTAMMENDEN FAKTOR UND/ODER p56Ick-TYROSINKINASE HEMMEN
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
IL148614A0 (en) 1999-09-15 2002-09-12 Warner Lambert Co Pteridinones as kinase inhibitors
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7569592B2 (en) 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
ATE446093T1 (de) 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
JP2003213463A (ja) 2002-01-17 2003-07-30 Sumitomo Chem Co Ltd 金属腐食防止剤および洗浄液
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
US7265378B2 (en) 2002-07-10 2007-09-04 E. I. Du Pont De Nemours And Company Electronic devices made with electron transport and/or anti-quenching layers
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2500727A1 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CA2512646A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
RU2330851C9 (ru) * 2003-05-23 2008-10-20 Центарис Гмбх ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, КОТОРЫЕ ОБУСЛОВЛЕНЫ НЕПРАВИЛЬНО НАПРАВЛЕННЫМИ ПРОЦЕССАМИ КЛЕТОЧНОЙ СИГНАЛЬНОЙ ТРАНСДУКЦИИ, СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
CA2533417A1 (en) 2003-07-21 2005-02-03 Mitchell A. Avery Design and synthesis of optimized ligands for ppar
CN1829709A (zh) 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
WO2005039587A1 (en) 2003-10-17 2005-05-06 4 Aza Bioscience Nv Heterocycle-substituted pteridine derivatives and their use in therapy
US20050209247A1 (en) 2003-11-07 2005-09-22 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
EP1687277B1 (en) 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
RU2377241C2 (ru) 2003-11-24 2009-12-27 Ф.Хоффманн-Ля Рош Аг Производные пиразоло-имидазопиримидина, обладающие антагонистической активностью в отношении кортикотропин-рилизинг фактора (crf)
PL1706385T3 (pl) 2003-12-23 2011-03-31 Astex Therapeutics Ltd Pochodne pirazolu jako modulatory kinazy białkowej
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
MX2007002434A (es) 2004-08-31 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
KR100875408B1 (ko) 2004-10-14 2008-12-23 에프. 호프만-라 로슈 아게 Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논
JP4966202B2 (ja) 2004-12-24 2012-07-04 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 治療または予防のための方法
CA2597447C (en) 2005-02-14 2014-03-25 Bionomics Limited Novel tubulin polymerisation inhibitors
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
JP2008540535A (ja) 2005-05-12 2008-11-20 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
BRPI0611521A2 (pt) 2005-05-18 2010-09-14 Wyeth Corp inibidores de 4,6-diamino-[1,7]naftiridina-3-carbonitrila de quìnase tpl2 e métodos de fabricação e uso dos mesmos
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
ES2456000T3 (es) 2005-08-26 2014-04-21 Merck Serono Sa Derivados de pirazina y su uso como inhibidores de PI3K
CA2628039A1 (en) 2005-11-11 2007-05-18 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
ME02736B (me) 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
EP2024342A2 (en) 2006-05-01 2009-02-18 Pfizer Products Incorporated Substituted 2-amino-fused heterocyclic compounds
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
EP2029600B1 (de) 2006-05-24 2012-03-14 Boehringer Ingelheim International GmbH Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
JP2009541460A (ja) 2006-07-03 2009-11-26 ベレナギング ヴォー クリスタラク ホガー オンダーヴェイル ヴェーテンザパーリク オンダージーク エン パシェンテンゾーク ヒスタミンｈ４受容体と相互作用する縮合二環式化合物
JP2008127446A (ja) 2006-11-20 2008-06-05 Canon Inc １，５−ナフチリジン化合物及び有機発光素子
EP2104501B1 (en) 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
MX2009006688A (es) 2006-12-21 2009-06-30 Plexxikon Inc Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
KR20090092287A (ko) 2006-12-22 2009-08-31 노파르티스 아게 Ｐｄｋ１ 억제를 위한 퀴나졸린
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
KR101251933B1 (ko) 2007-06-20 2013-04-09 미쓰비시 타나베 파마 코퍼레이션 신규한 말론산술폰아미드 유도체 및 그 의약 용도
WO2008155378A1 (en) 2007-06-21 2008-12-24 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
CA2725185C (en) 2008-05-23 2016-10-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
JP5662346B2 (ja) 2009-01-21 2015-01-28 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ 新規二環式抗生物質
CA2750051A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
ES2736198T3 (es) 2009-06-12 2019-12-26 Abivax Compuestos útiles para tratar el cáncer
NZ598294A (en) 2009-09-03 2013-07-26 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US9096590B2 (en) 2010-05-24 2015-08-04 Intellikine Llc Substituted benzoxazoles as PI3 kinase inhibitors
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN104053442B (zh) 2011-08-26 2017-06-23 润新生物公司 某些化学实体、组合物及方法
CN108794411B (zh) 2011-09-14 2022-06-07 润新生物公司 某些化学实体、组合物及方法
WO2013043935A1 (en) 2011-09-21 2013-03-28 Neupharma, Inc. Certain chemical entites, compositions, and methods
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
AU2013228389A1 (en) 2012-03-08 2014-09-25 Astellas Pharma Inc. Novel FGFR3 fusion product
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022062B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
WO2015144804A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
IL232083A0 (en) 2014-05-28
AR088567A1 (es) 2014-06-18
MY185666A (en) 2021-05-28
US20160235744A1 (en) 2016-08-18
EA027563B1 (ru) 2017-08-31
US20140288053A1 (en) 2014-09-25
AU2012328170B2 (en) 2017-08-24
MX2014004855A (es) 2014-08-21
EA201490891A1 (ru) 2014-09-30
TW201333004A (zh) 2013-08-16
CN104011051B (zh) 2017-05-10
US9309242B2 (en) 2016-04-12
UA111386C2 (uk) 2016-04-25
DK2776435T3 (en) 2018-10-15
ES2688868T3 (es) 2018-11-07
CN104011051A (zh) 2014-08-27
IN2014MN00948A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-04-24
KR20140096034A (ko) 2014-08-04
EP2776435A1 (en) 2014-09-17
JP6169583B2 (ja) 2017-07-26
IL232083B (en) 2018-06-28
CL2014001065A1 (es) 2014-07-25
ECSP14013325A (es) 2015-04-30
AP2014007540A0 (en) 2014-03-31
MX353654B (es) 2018-01-22
AU2012328170A1 (en) 2014-05-22
UY34418A (es) 2013-05-31
CA2853390C (en) 2020-12-15
WO2013061080A1 (en) 2013-05-02
BR112014010206B1 (pt) 2020-12-08
LT2776435T (lt) 2018-10-10
KR102066496B1 (ko) 2020-01-15
CO6940422A2 (es) 2014-05-09
US10045982B2 (en) 2018-08-14
TWI602814B (zh) 2017-10-21
JO3419B1 (ar) 2019-10-20
AP4060A (en) 2017-03-08
SG11201401055XA (en) 2014-09-26
NI201400032A (es) 2015-11-24
EP2776435B1 (en) 2018-06-27
CR20140190A (es) 2014-05-26
SI2776435T1 (sl) 2018-11-30
PH12014500867A1 (en) 2014-06-30
BR112014010206B8 (pt) 2021-08-03
NZ622702A (en) 2016-08-26
HRP20181533T1 (hr) 2018-11-16
BR112014010206A2 (pt) 2017-05-16
JP2014534211A (ja) 2014-12-18
CA2853390A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
GB201118656D0 (en) New compounds
MX349004B (es) Nuevos compuestos.
MX366899B (es) Nuevos compuestos.
IN2014MN00986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB201209613D0 (en) New compounds
IN2012MN02591A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014MN00988A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
TN2015000278A1 (en) Autotaxin inhibitors
TW201613901A (en) New compounds
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
IN2014DN03010A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
IN2014DN10683A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)